Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen Russell

Showing results (61-70 of 99) with videos related to

Pageof 10
Sort By:
Bone Marrow Transplantation|June 11, 2020
Outcomes with early vs. deferred stem cell transplantation in light chain amyloidosisNadine Abdallah, Surbhi Sidana, Angela Dispenzieri, et al.
Cell Host & Microbe|July 31, 2018
A Gut Commensal-Produced Metabolite Mediates Colonization Resistance to Salmonella InfectionAmanda Jacobson, Lilian Lam, Manohary Rajendram, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 23, 2013
Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosisTaxiarchis V Kourelis, Shaji K Kumar, Morie A Gertz, et al.
American Journal of Hematology|October 13, 2016
Beta-blockers improve survival outcomes in patients with multiple myeloma: a retrospective evaluationYi L Hwa, Qian Shi, Shaji K Kumar, et al.
Ophthalmology|August 25, 2019
Efficacy, Safety, and Durability of Voretigene Neparvovec-rzyl in RPE65 Mutation-Associated Inherited Retinal Dystrophy: Results of Phase 1 and 3 TrialsAlbert M Maguire, Stephen Russell, Jennifer A Wellman, et al.
Haematologica|August 2, 2016
Immunoparesis status in immunoglobulin light chain amyloidosis at diagnosis affects response and survival by regimen typeEli Muchtar, Angela Dispenzieri, Shaji K Kumar, et al.
American Journal of Hematology|July 18, 2018
Serum free light chain measurements to reduce 24-h urine monitoring in patients with multiple myeloma with measurable urine monoclonal proteinMarcella Tschautscher, Vincent Rajkumar, Angela Dispenzieri, et al.
Blood|October 13, 2016
The prognostic value of multiparametric flow cytometry in AL amyloidosis at diagnosis and at the end of first-line treatmentEli Muchtar, Dragan Jevremovic, Angela Dispenzieri, et al.
British Journal of Haematology|November 24, 2011
A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myelomaMeaghan L Khan, Craig B Reeder, Shaji K Kumar, et al.
American Journal of Hematology|December 17, 2019
Implications and outcomes of MRD-negative multiple myeloma patients with immunofixation positivityMarcella Tschautscher, Dragan Jevremovic, Francis K Buadi, et al.
Pageof 10

Showing results (61-70 of 99) with videos related to

Sort By:
Pageof 10
Bone Marrow Transplantation|June 11, 2020
Outcomes with early vs. deferred stem cell transplantation in light chain amyloidosisNadine Abdallah, Surbhi Sidana, Angela Dispenzieri, et al.
Cell Host & Microbe|July 31, 2018
A Gut Commensal-Produced Metabolite Mediates Colonization Resistance to Salmonella InfectionAmanda Jacobson, Lilian Lam, Manohary Rajendram, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 23, 2013
Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosisTaxiarchis V Kourelis, Shaji K Kumar, Morie A Gertz, et al.
American Journal of Hematology|October 13, 2016
Beta-blockers improve survival outcomes in patients with multiple myeloma: a retrospective evaluationYi L Hwa, Qian Shi, Shaji K Kumar, et al.
Ophthalmology|August 25, 2019
Efficacy, Safety, and Durability of Voretigene Neparvovec-rzyl in RPE65 Mutation-Associated Inherited Retinal Dystrophy: Results of Phase 1 and 3 TrialsAlbert M Maguire, Stephen Russell, Jennifer A Wellman, et al.
Haematologica|August 2, 2016
Immunoparesis status in immunoglobulin light chain amyloidosis at diagnosis affects response and survival by regimen typeEli Muchtar, Angela Dispenzieri, Shaji K Kumar, et al.
American Journal of Hematology|July 18, 2018
Serum free light chain measurements to reduce 24-h urine monitoring in patients with multiple myeloma with measurable urine monoclonal proteinMarcella Tschautscher, Vincent Rajkumar, Angela Dispenzieri, et al.
Blood|October 13, 2016
The prognostic value of multiparametric flow cytometry in AL amyloidosis at diagnosis and at the end of first-line treatmentEli Muchtar, Dragan Jevremovic, Angela Dispenzieri, et al.
British Journal of Haematology|November 24, 2011
A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myelomaMeaghan L Khan, Craig B Reeder, Shaji K Kumar, et al.
American Journal of Hematology|December 17, 2019
Implications and outcomes of MRD-negative multiple myeloma patients with immunofixation positivityMarcella Tschautscher, Dragan Jevremovic, Francis K Buadi, et al.
Pageof 10